BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (“Shares”) of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Merck today announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers.

NRx Pharmaceuticals, Inc. today announced that its Investigational New Drug Application (IND) for the use of NRX-101, the company’s patented combination of D-cycloserine and lurasidone, for the treatment of complicated Urinary Tract infections (cUTI), received clearance from the US FDA.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’) today announced that the Company has transferred ownership, as of May 2023, of the existing U.S. Food and Drug Administration (FDA) New Drug Application (NDA) of the investigational MAP originally intended for the epidermal delivery of zolmitriptan1 (also known as M207) for the treatment of migraine attacks in adults.

Sunstone Therapies announces the publication in Cancer of the full results and methodology for its phase 2 clinical trial assessing the safety, tolerability, feasibility, and preliminary efficacy of psilocybin-assisted therapy to treat cancer patients suffering from major depressive disorder.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-Cell Receptors (TCRs) directed against multiple cancer neoantigens.

Replay today announced a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME.

Achilles Therapeutics plc today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward.

EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the prevention of symptomatic COVID-19.